Obesity medications, while gaining attention in Congress for potential coverage expansion, present significant risks and financial implications. These drugs come with known side effects, including muscle loss, increased frailty, higher rates of thyroid cancer, kidney dysfunction, and pancreatitis, potentially compromising health outcomes, particularly in older populations. The Treat and Reduce Obesity Act aims to cover these medications for 74% of Americans, which could result in over $3 trillion in annual taxpayer-funded expenses. This investment is unlikely to address the underlying causes of obesity and may primarily benefit foreign pharmaceutical companies, as similar drugs are not the standard in European countries. Additionally, recommendations are being made for these medications to be prescribed to adolescents, raising concerns about reliance on lifelong treatments without adequate alternatives like diet and exercise.